The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Myeloma: follow-up of GRIFFIN study
Jonathan Kaufman, MD, Emory University School of Medicine, Atlanta, GA, briefly highlights preliminary findings from the Phase II randomized GRIFFIN trial (NCT02874742) in eligible newly diagnosed multiple myeloma patients. In this video, Dr Kaufman provides an update on the longer follow-up of the GRIFFIN study, where daratumumab is added to a lenalidomide, bortezomib and dexamethasone (RVd) backbone. Dr Kaufman draws focus on the ongoing improvements in deep responses, MRD negativity rate, and gives further input from a toxicity perspective. This interview took place at the 63rd ASH Annual Meeting and Exposition, Atlanta, 2021.
